Pascal Alfonsi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pascal Alfonsi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Marcel Chauvin
Professor and Chair
5 shared publicationsDaniel I. Sessler
Professor and Chair, Department of Outcomes Research, the Cleveland Clinic, Cleveland, Ohio
4 shared publicationsBruno Guignard
Attending Anesthesiologist
3 shared publicationsAndrea Passard
Attending Anesthesiologist
2 shared publications- Isabelle Javerliat
Department of Vascular Surgery, CHU Tours, Cédex, France
2 shared publications - Marc Coggia
Department of Vascular Surgery, Ambroise Paré University Hospital, Boulogne-Billancourt, France
2 shared publications
Latest Publications
- 1 July 2009
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 111 (1) , 102-109
Nefopam and Alfentanil Additively Reduce the Shivering Threshold in Humans whereas Nefopam and Clonidine Do Not
Background: Induction of therapeutic hypothermia is often complicated by shivering. Nefopam reduces the shivering threshold with minimal side effects. Consequently, nefopam is an attractive component for induction of therapeutic hypothermia. However, nefopam alone is insufficient; it will thus need to be combined with another drug. Clonidine and alfentanil each reduce the shivering threshold. This study, therefore, tested the hypothesis that nefopam, combined either with clonidine or alfentanil, synergistically reduces the shivering threshold. Methods: For each combination, ten volunteers were studied on 4 days. Combination 1: (1) control (no drug); (2) nefopam (100 ng/ml); (3) clonidine (2.5 microg/kg); and (4) nefopam plus clonidine (100 ng/ml and 2.5 microg/kg, respectively). Combination 2: (1) control (no drug); (2) nefopam (100 ng/ml); (3) alfentanil (150 ng/ml); and (4) nefopam plus alfentanil (100 ng/ml and 150 ng/ml, respectively). Lactated Ringer's solution (approximately 4 degrees C) was infused to decrease core temperature. Mean skin temperature was maintained at 31 degrees C. The core temperature that increased oxygen consumption to more than 25% of baseline identified the shivering threshold. Results: With nefopam and clonidine, the shivering thresholds were significantly lower than on the control day. The shivering threshold decreased significantly less than would be expected on the basis of the individual effects of each drug (P = 0.034). In contrast, the interaction between nefopam and alfentanil on shivering was additive, meaning that the combination reduced the shivering threshold as much as would be expected by the individual effect of each drug. Conclusions: Nefopam and alfentanil additively reduce the shivering threshold, but nefopam and clonidine do not.
- 1 July 2009
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 111 (1) , 102-109
Nefopam and Alfentanil Additively Reduce the Shivering Threshold in Humans whereas Nefopam and Clonidine Do Not
Background: Induction of therapeutic hypothermia is often complicated by shivering. Nefopam reduces the shivering threshold with minimal side effects. Consequently, nefopam is an attractive component for induction of therapeutic hypothermia. However, nefopam alone is insufficient; it will thus need to be combined with another drug. Clonidine and alfentanil each reduce the shivering threshold. This study, therefore, tested the hypothesis that nefopam, combined either with clonidine or alfentanil, synergistically reduces the shivering threshold. Methods: For each combination, ten volunteers were studied on 4 days. Combination 1: (1) control (no drug); (2) nefopam (100 ng/ml); (3) clonidine (2.5 microg/kg); and (4) nefopam plus clonidine (100 ng/ml and 2.5 microg/kg, respectively). Combination 2: (1) control (no drug); (2) nefopam (100 ng/ml); (3) alfentanil (150 ng/ml); and (4) nefopam plus alfentanil (100 ng/ml and 150 ng/ml, respectively). Lactated Ringer's solution (approximately 4 degrees C) was infused to decrease core temperature. Mean skin temperature was maintained at 31 degrees C. The core temperature that increased oxygen consumption to more than 25% of baseline identified the shivering threshold. Results: With nefopam and clonidine, the shivering thresholds were significantly lower than on the control day. The shivering threshold decreased significantly less than would be expected on the basis of the individual effects of each drug (P = 0.034). In contrast, the interaction between nefopam and alfentanil on shivering was additive, meaning that the combination reduced the shivering threshold as much as would be expected by the individual effect of each drug. Conclusions: Nefopam and alfentanil additively reduce the shivering threshold, but nefopam and clonidine do not.
- 28 February 2009
- Published by Elsevier in Annales de Chirurgie Vasculaire
- Vol. 23 (1) , 47-52
Traitement totalement laparoscopique des anévrismes de l'aorte abdominale à collet court
- 28 February 2009
- Published by Elsevier in Annales de Chirurgie Vasculaire
- Vol. 23 (1) , 47-52
Traitement totalement laparoscopique des anévrismes de l'aorte abdominale à collet court
- 1 March 2008
- Published by Elsevier in Anales de Cirugía Vascular
- Vol. 22 (2) , 246-252
Bypass aortobifemoral laparoscópico total: resultados a corto y medio plazo
- 1 March 2008
- Published by Elsevier in Anales de Cirugía Vascular
- Vol. 22 (2) , 246-252
Bypass aortobifemoral laparoscópico total: resultados a corto y medio plazo
- Open Access
- 1 January 2004
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 100 (1) , 37-43
Nefopam, a Nonsedative Benzoxazocine Analgesic, Selectively Reduces the Shivering Threshold in Unanesthetized Subjects
Background: The analgesic nefopam does not compromise ventilation, is minimally sedating, and is effective as a treatment for postoperative shivering. The authors evaluated the effects of nefopam on the major thermoregulatory responses in humans: sweating, vasoconstriction, and shivering. Methods: Nine volunteers were studied on three randomly assigned days: (1) control (saline), (2) nefopam at a target plasma concentration of 35 ng/ml (low dose), and (3) nefopam at a target concentration of 70 ng/ml (high dose, approximately 20 mg total). Each day, skin and core temperatures were increased to provoke sweating and then reduced to elicit peripheral vasoconstriction and shivering. The authors determined the thresholds (triggering core temperature at a designated skin temperature of 34 degrees C) by mathematically compensating for changes in skin temperature using the established linear cutaneous contributions to control of each response. Results: Nefopam did not significantly modify the slopes for sweating (0.0 +/- 4.9 degrees C. microg-1. ml; r2 = 0.73 +/- 0.32) or vasoconstriction (-3.6 +/- 5.0 degrees C. microg-1. ml; r2 = -0.47 +/- 0.41). In contrast, nefopam significantly reduced the slope of shivering (-16.8 +/- 9.3 degrees C. microg-1. ml; r2 = 0.92 +/- 0.06). Therefore, high-dose nefopam reduced the shivering threshold by 0.9 +/- 0.4 degrees C (P < 0.001) without any discernible effect on the sweating or vasoconstriction thresholds. Conclusions: Most drugs with thermoregulatory actions-including anesthetics, sedatives, and opioids-synchronously reduce the vasoconstriction and shivering thresholds. However, nefopam reduced only the shivering threshold. This pattern has not previously been reported for a centrally acting drug. That pharmacologic modulations of vasoconstriction and shivering can be separated is of clinical and physiologic interest.
- 1 January 2004
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 100 (1) , 37-43
Open AccessNefopam, a Nonsedative Benzoxazocine Analgesic, Selectively Reduces the Shivering Threshold in Unanesthetized Subjects
Background: The analgesic nefopam does not compromise ventilation, is minimally sedating, and is effective as a treatment for postoperative shivering. The authors evaluated the effects of nefopam on the major thermoregulatory responses in humans: sweating, vasoconstriction, and shivering. Methods: Nine volunteers were studied on three randomly assigned days: (1) control (saline), (2) nefopam at a target plasma concentration of 35 ng/ml (low dose), and (3) nefopam at a target concentration of 70 ng/ml (high dose, approximately 20 mg total). Each day, skin and core temperatures were increased to provoke sweating and then reduced to elicit peripheral vasoconstriction and shivering. The authors determined the thresholds (triggering core temperature at a designated skin temperature of 34 degrees C) by mathematically compensating for changes in skin temperature using the established linear cutaneous contributions to control of each response. Results: Nefopam did not significantly modify the slopes for sweating (0.0 +/- 4.9 degrees C. microg-1. ml; r2 = 0.73 +/- 0.32) or vasoconstriction (-3.6 +/- 5.0 degrees C. microg-1. ml; r2 = -0.47 +/- 0.41). In contrast, nefopam significantly reduced the slope of shivering (-16.8 +/- 9.3 degrees C. microg-1. ml; r2 = 0.92 +/- 0.06). Therefore, high-dose nefopam reduced the shivering threshold by 0.9 +/- 0.4 degrees C (P < 0.001) without any discernible effect on the sweating or vasoconstriction thresholds. Conclusions: Most drugs with thermoregulatory actions-including anesthetics, sedatives, and opioids-synchronously reduce the vasoconstriction and shivering thresholds. However, nefopam reduced only the shivering threshold. This pattern has not previously been reported for a centrally acting drug. That pharmacologic modulations of vasoconstriction and shivering can be separated is of clinical and physiologic interest.
- Open Access
- 18 November 2003
- Published by Wiley in Anaesthesia
- Vol. 58 (12) , 1228-1234
Effect of postoperative skin‐surface warming on oxygen consumption and the shivering threshold*
Summary: Cutaneous warming is reportedly an effective treatment for shivering during epidural and after general anaesthesia. We quantified the efficacy of cutaneous warming as a treatment for shivering. Unwarmed surgical patients (final intra‐operative core temperatures ∼ 35 °C) were randomly assigned to be covered with a blanket ( n = 9) or full‐body forced‐air cover ( n = 9). Shivering was evaluated clinically and by oxygen consumption. Forced‐air heating increased mean‐skin temperature (mean (SD) 35.7 °C (0.4) vs. 33.2 °C (0.8); p < 0.0001) and lowered core temperature at the shivering threshold (35.7 °C (0.2) vs. 36.4 °C(0.2); p < 0.0001). Active warming improved thermal comfort and significantly reduced oxygen consumption from 9.7 (4.4) ml.min −1 .kg −1 to 5.6 (1.9) ml.min −1 .kg −1 (p = 0.038). However, the duration of shivering was similar in the unwarmed (37 min (11)) and active warming (36 min (10)) groups. Core temperature contributed about four times as much as skin temperature to control of shivering. Cutaneous warming improved thermal comfort and reduced metabolic stress in postoperative patients, but did not quickly obliterate shivering.
- 18 November 2003
- Published by Wiley in Anaesthesia
- Vol. 58 (12) , 1228-1234
Open AccessEffect of postoperative skin‐surface warming on oxygen consumption and the shivering threshold*
Summary: Cutaneous warming is reportedly an effective treatment for shivering during epidural and after general anaesthesia. We quantified the efficacy of cutaneous warming as a treatment for shivering. Unwarmed surgical patients (final intra‐operative core temperatures ∼ 35 °C) were randomly assigned to be covered with a blanket ( n = 9) or full‐body forced‐air cover ( n = 9). Shivering was evaluated clinically and by oxygen consumption. Forced‐air heating increased mean‐skin temperature (mean (SD) 35.7 °C (0.4) vs. 33.2 °C (0.8); p < 0.0001) and lowered core temperature at the shivering threshold (35.7 °C (0.2) vs. 36.4 °C(0.2); p < 0.0001). Active warming improved thermal comfort and significantly reduced oxygen consumption from 9.7 (4.4) ml.min −1 .kg −1 to 5.6 (1.9) ml.min −1 .kg −1 (p = 0.038). However, the duration of shivering was similar in the unwarmed (37 min (11)) and active warming (36 min (10)) groups. Core temperature contributed about four times as much as skin temperature to control of shivering. Cutaneous warming improved thermal comfort and reduced metabolic stress in postoperative patients, but did not quickly obliterate shivering.
- 1 May 2003
- Vol. 69 (5) , 438-42
Postanaesthetic shivering. Epidemiology, pathophysiology and approaches to prevention and management.
Postanaesthetic shivering is one of the leading causes of discomfort for patients recovering from general anesthesia. During EMG records, the distinguishing factor from shivering in fully awake patients is the existence of clonus similar to that recorded in patients with spinal cord transection. They coexist with the classic waxing and waning signals associated with cutaneous vasoconstriction (thermoregulatory shivering). The causes responsible for their appearance primarily include hypothermia, which sets in due to thermoregulation inhibition by anesthetics. However, we also note the existence of shivering associated with cutaneous vasodilatation (non-thermoregulatory shivering) one of the origins of which is postoperative pain. Apart from the discomfort and aggravated pain, postanaesthetic shivering raises metabolic demand proportionally to the solicited muscle mass and the patient's cardiac capacities. No link has been demonstrated between their occurrence and an increase in cardiac morbidity but it is preferable to avoid postanaesthetic shivering since it is oxygen draining. Prevention mainly entails preventing hypothermia by actively rewarming the patient. Postoperative skin surface rewarming is a way of obtaining the threshold shivering temperature while raising the skin temperature and improving the patient's comfort. However, it is less efficient than certain drugs such as meperidine, nefopam or tramadol, which act by reducing the shivering threshold temperature.
- 1 May 2003
- Vol. 69 (5) , 438-42
Postanaesthetic shivering. Epidemiology, pathophysiology and approaches to prevention and management.
Postanaesthetic shivering is one of the leading causes of discomfort for patients recovering from general anesthesia. During EMG records, the distinguishing factor from shivering in fully awake patients is the existence of clonus similar to that recorded in patients with spinal cord transection. They coexist with the classic waxing and waning signals associated with cutaneous vasoconstriction (thermoregulatory shivering). The causes responsible for their appearance primarily include hypothermia, which sets in due to thermoregulation inhibition by anesthetics. However, we also note the existence of shivering associated with cutaneous vasodilatation (non-thermoregulatory shivering) one of the origins of which is postoperative pain. Apart from the discomfort and aggravated pain, postanaesthetic shivering raises metabolic demand proportionally to the solicited muscle mass and the patient's cardiac capacities. No link has been demonstrated between their occurrence and an increase in cardiac morbidity but it is preferable to avoid postanaesthetic shivering since it is oxygen draining. Prevention mainly entails preventing hypothermia by actively rewarming the patient. Postoperative skin surface rewarming is a way of obtaining the threshold shivering temperature while raising the skin temperature and improving the patient's comfort. However, it is less efficient than certain drugs such as meperidine, nefopam or tramadol, which act by reducing the shivering threshold temperature.
- 1 September 2002
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 96 (Sup 2) , A257
Nefopam Inhibits Thermoregulation and Possesses a Specific Anti-Shivering Effect
- 1 September 2002
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 96 (Sup 2) , A257
Nefopam Inhibits Thermoregulation and Possesses a Specific Anti-Shivering Effect
- 1 July 2002
- Published by Elsevier in The American Journal of Surgery
- Vol. 184 (1) , 37-40
Mild hypothermia does not increase bacterial proliferation on implanted vascular grafts
- 1 July 2002
- Published by Elsevier in The American Journal of Surgery
- Vol. 184 (1) , 37-40
Mild hypothermia does not increase bacterial proliferation on implanted vascular grafts
- 1 January 2001
- Published by Springer Nature in Drugs
- Vol. 61 (15) , 2193-2205
Postanaesthetic Shivering
Along with nausea and vomiting, postanaesthetic shivering is one of the leading causes of discomfort for patients recovering from general anaesthesia. The distinguishing factor during electromyogram...
- 1 January 2001
- Published by Springer Nature in Drugs
- Vol. 61 (15) , 2193-2205
Postanaesthetic Shivering
Along with nausea and vomiting, postanaesthetic shivering is one of the leading causes of discomfort for patients recovering from general anaesthesia. The distinguishing factor during electromyogram...
- 1 July 1998
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 89 (1) , 43-48
The Effects of Meperidine and Sufentanil on the Shivering Threshold in Postoperative Patients
Unlabelled: BACKGROUND. Meperidine (pethidine) reportedly treats postoperative shivering better than equianalgesic doses of other mu-receptor agonists. The authors' first goal was to develop a method to accurately determine postoperative shivering thresholds, and then to determine the extent to which meperidine and sufentanil inhibit postoperative shivering. Methods: A computer-controlled infusion was started before operation in 30 patients, with target plasma concentrations of 0.15, 0.30, or 0.60 microg/ml meperidine or 0.1, 0.15, or 0.2 ng/ ml sufentanil targeted; patients were randomly assigned to each drug and concentration. The infusion was continued throughout surgery and recovery. Anesthesia was maintained with nitrous oxide and isoflurane. Core temperatures were approximately 34 degrees C by the end of surgery. The compensated core temperature at which visible shivering and a 20% decrease in steady-state oxygen consumption was recorded identified the shivering threshold. A blood sample for opioid concentration was obtained from each patient at this time. The ability of each opioid to reduce the shivering threshold was evaluated using linear regression. Results: End-tidal isoflurane concentrations were <0.2% in each group at the time of extubation, and shivering occurred approximately 1 h later. Meperidine linearly decreased the shivering threshold: threshold (degrees C) = -2.8 x [meperidine (microg/ml)] + 36.2; r2 = 0.64, P = 0.0005. Sufentanil also linearly decreased the shivering threshold: threshold (degrees C) = -7.8 x [sufentanil (ng/ ml)] + 36.9; r2 = 0.46, P = 0.02. Conclusions: At a given dose, sufentanil inhibited shivering 2,800 times better than meperidine. However, the equianalgesic ratio of these drugs is approximately 4,900. That is, meperidine inhibited shivering better than would be expected based on the equianalgesic potency ratio. These data are thus consistent with clinical observations suggesting that meperidine indeed possesses special antishivering activity.
- 1 July 1998
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 89 (1) , 43-48
The Effects of Meperidine and Sufentanil on the Shivering Threshold in Postoperative Patients
Unlabelled: BACKGROUND. Meperidine (pethidine) reportedly treats postoperative shivering better than equianalgesic doses of other mu-receptor agonists. The authors' first goal was to develop a method to accurately determine postoperative shivering thresholds, and then to determine the extent to which meperidine and sufentanil inhibit postoperative shivering. Methods: A computer-controlled infusion was started before operation in 30 patients, with target plasma concentrations of 0.15, 0.30, or 0.60 microg/ml meperidine or 0.1, 0.15, or 0.2 ng/ ml sufentanil targeted; patients were randomly assigned to each drug and concentration. The infusion was continued throughout surgery and recovery. Anesthesia was maintained with nitrous oxide and isoflurane. Core temperatures were approximately 34 degrees C by the end of surgery. The compensated core temperature at which visible shivering and a 20% decrease in steady-state oxygen consumption was recorded identified the shivering threshold. A blood sample for opioid concentration was obtained from each patient at this time. The ability of each opioid to reduce the shivering threshold was evaluated using linear regression. Results: End-tidal isoflurane concentrations were <0.2% in each group at the time of extubation, and shivering occurred approximately 1 h later. Meperidine linearly decreased the shivering threshold: threshold (degrees C) = -2.8 x [meperidine (microg/ml)] + 36.2; r2 = 0.64, P = 0.0005. Sufentanil also linearly decreased the shivering threshold: threshold (degrees C) = -7.8 x [sufentanil (ng/ ml)] + 36.9; r2 = 0.46, P = 0.02. Conclusions: At a given dose, sufentanil inhibited shivering 2,800 times better than meperidine. However, the equianalgesic ratio of these drugs is approximately 4,900. That is, meperidine inhibited shivering better than would be expected based on the equianalgesic potency ratio. These data are thus consistent with clinical observations suggesting that meperidine indeed possesses special antishivering activity.